Key Insights

Highlights

Treatment Research

4 treatments under study, led by Tislelizumab

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

1Total
P 1 (1)

Trial Status

Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT05768932Phase 1Recruiting

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

NCT00185523Terminated

Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)

Showing all 2 trials

Research Network

Common Treatments

  • Tislelizumab1
  • Allogeneic Hematopoietic Cell Transplantation1
  • Bal08911
  • Paclitaxel1

Active Sponsors

  • Sillajen Inc1
  • Stanford University1

Related Conditions

  • Leukemia Acute Lymphoid Leukemia All1
  • Gastric Cancer1
  • Leukemia Chronic Myelogenous Leukemia Cml1
  • Leukemia Acute Promyelocytic Leukemia Apl1
  • Leukemia Lymphocytic Acute1

Activity Timeline